Table 2.
Donors’ and organs’ characteristics. Data are presented as mean ± SD and median (min-max) for normally distributed and skewed quantitative variables respectively; and n (%) for nominal variables.
| Characteristics | L-Carnitine group (N = 33) | Placebo group (N = 39) | P Values |
|---|---|---|---|
| Age (y) | 40.06 ± 15.79 | 42.36 ± 11.66 | 0.680 |
| Sex (male) | 27 (81.8) | 26 (66.7) | 0.146 |
| Body mass index (kg/m2) | 24.95 ± 3.34 | 25.58 ± 1.97 | 0.344 |
| Creatinine (mg/dL) | 1.40 (0.60-7.10) | 1.60 (0.70-9.90) | 0.469 |
| Aspartate aminotransferase (IU/L) | 44 (11-415) | 55 (7-293) | 0.973 |
| Alanine aminotransferase (IU/L) | 35 (9-157) | 38 (10-340) | 0.982 |
| Who were administered vasoactive agent | 30 (90.9) | 36 (92.3) | 1.000 |
| Type of vasoactive agent | 0.756 | ||
| Norepinephrine | 9 (30) | 8 (22.2) | |
| Dopamine | 20 (66.7) | 27 (75) | |
| Norepinephrine + dopamine | 1 (3.3) | 1 (2.8) | |
| Intensive care unit stay (days) | 4 (1-18) | 4 (1-21) | 0.641 |
| Cardiopulmonary resuscitation | 11 (33.3) | 7 (17.9) | 0.133 |
| Cause of brain death | 0.892 | ||
| Trauma | 8 (24.2) | 7 (17.9) | |
| Cerebrovascular accident | 15 (45.4) | 20 (51.3) | |
| Toxicity | 5 (15.2) | 7 (17.9) | |
| Others | 5 (15.2) | 5 (12.8) | |
| Cold ischemic time (min) | 311.36 ± 57.54 | 313 ± 72.5 | 0.991 |
| Warm ischemic time (min) | 40.91 ± 12.58 | 40.95 ± 13.67 | 0.865 |
| An hepatic phase time (min) | 64.52 ± 22.47 | 64.95 ± 21.80 | 0.934 |
| Expanded donor criteria | 1 (0-3) | 1 (0-2) | 0.76 |